Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28454710 | 0.68 | CYP1A2 (0.38) | GPR3ACHEKMT2ACYP1A2PLCG1 | |
| SCHEMBL9877879 | 0.68 | MEN1 (0.35) | ACHEMEN1KMT2ACYP1A2 | |
| SCHEMBL29412540 | 0.66 | KEAP1 (0.39) | GPR3MEN1KMT2ANOX1PLCG1 | |
| SCHEMBL29844652 | 0.64 | MAOA (0.54) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| SCHEMBL19820978 | 0.64 | GPR3 (0.52) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| SCHEMBL290638 | 0.64 | MAOA (0.54) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| SCHEMBL29958223 | 0.64 | MAOA (0.54) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| Water SCHEMBL7420168 | 0.62 | MAOA (0.53) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| SCHEMBL11750709 | 0.60 | CES1 (0.39) | GPR3MEN1KMT2ANOX1CYP1A2 | |
| SCHEMBL61667 | 0.60 | CA1 (0.47) | GPR3MEN1KMT2ANOX1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846898-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotide having reduced internucleotide charge | Lieure Cornu LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | LIEVRE CORNU LLC (US) | 2010-12-09 | — | — | US | disclosed |
| US-7745591-B2 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | Lievre Cornu, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1334111-A4 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | LIEVRE CORNU LLC (US) | 2006-12-28 | — | — | US | disclosed |
| US-20060141020-A1 | Liposomes containing oligonucleotides | GEORGETOWN UNIVERSITY (US) | 2006-06-29 | — | — | US | disclosed |
| US-7067641-B2 | Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge | LIEVRE CORNU LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050148528-A1 | Method for reducing platelet count | NEOPHARM, INC (US) | 2005-07-07 | — | — | US | disclosed |
| EP-0806966-B1 | CATIONIC COPOLYMERS OF VINYLAMINE AND VINYL ALCOHOL FOR THE DELIVERY OF OLIGONUCLEOTIDES | AMGEN INC (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20040116687-A1 | oligonucleotides having reduced internucleotide charge and enhanced nuclease resistance | AGILENT TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| EP-1334111-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | Dellinger, Douglas J. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020160038-A1 | Liposomes containing oligonucleotides | GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE | 2002-10-31 | — | — | US | disclosed |
| WO-2002032912-A2 | PHOSPHINOAMIDITE CARBOXYLATES AND ANALOGS THEREOF IN THE SYNTHESIS OF OLIGONUCLEOTIDES HAVING REDUCED INTERNUCLEOTIDE CHARGE | DELLINGER DOUGLAS J (US) | 2002-04-25 | — | — | WO | disclosed |
| US-6333314-B1 | RADIOSENSITIZING TUMOR TISSUE BY ADMINISTRATION OF FORMULATION COMPRISING CATIONIC LIPOSOME, PHOSPHATIDYLCHOLINE AND CHOLESTEROL, AND ENCAPSULATED ANTISENSE OLIGONUCLEOTIDE | GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE | 2001-12-25 | — | — | US | disclosed |
| US-6126965-A | CATIONIC LIPOSOMES OF DIMETHYLDIOCTADECYLAMMONIUM BROMIDE, PHOSPHATIDYLCHOLINE AND CHOLESTEROL WITH ENCAPSULATION | GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-10-03 | — | — | US | disclosed |
| US-6124099-A | Method for placing a photo-cross-linking agent at specific internal sites within the sequence of synthetic strands of ribonucleic acids | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0806966-A1 | CATIONIC COPOLYMERS OF VINYLAMINE AND VINYL ALCOHOL FOR THE DELIVERY OF OLIGONUCLEOTIDES | AMGEN INC. (US) | 1997-11-19 | — | — | EP | disclosed |
| CN-1165508-A | Synthesis of 35S-labeled oligonucleotides with 3H-1,2-benzodithiol-3-1,1-dioxide | HYBRIDON INC (US) | 1997-11-19 | — | — | CN | disclosed |
| WO-1996022792-A1 | CATIONIC COPOLYMERS OF VINYLAMINE AND VINYL ALCOHOL FOR THE DELIVERY OF OLIGONUCLEOTIDES | AMGEN INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| WO-1996011266-A2 | METHOD FOR INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND OLIGONUCLEOTIDES FOR USE THEREIN | AMGEN INC. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311960-A1 | Phosphinoamidite Carboxylates and Analogs Thereof in the Synthesis of Oligonucleotide Having Reduced Internucleotide Charge | NSUN2, POLL, DUT | GPR3 3412/4885ACHE 3200/4885MEN1 2675/4885 |
| US-20060293511-A1 | phosphinocarboxylate and phosphonocarboxylate oligonucleotides having enhanced nuclease resistance | NSUN2, ADAR, POLL | GPR3 4448/4885ACHE 2882/4885MEN1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.